Read + Share
Kim CG, Kim M, Hwang J, Kim ST, et al. First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF
V600-mutant advanced melanoma. J Am Acad Dermatol 2022 Sep 3. pii: S0190-9622(22)02443.
PMID: 36068115
|
 |
|
Kim CG, Kim M, Hwang J, Kim ST, et al. First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF
V600-mutant advanced melanoma. J Am Acad Dermatol 2022 Sep 3. pii: S0190-9622(22)02443.
PMID: 36068115
|
|
|
|